Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | DPP4 | P27487 | 14/20 | 0.41 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | MMP8 | P22894 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | FAP | Q12884 | 1/20 | 0.35 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.35 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL332351 | 0.92 | ALDH1A1 (0.46) | ALDH1A1TSHRSMN1; SMN2DPP4DPP9 | |
| SCHEMBL3770091 | 0.87 | ALDH1A1 (0.41) | ALDH1A1TSHRSMN1; SMN2DPP4 | |
| SCHEMBL3770522 | 0.84 | ALDH1A1 (0.43) | ALDH1A1TSHRSMN1; SMN2KMT2AMMP8 | |
| SCHEMBL3778951 | 0.81 | ALDH1A1 (0.41) | ALDH1A1TSHRSMN1; SMN2KMT2AMMP8 | |
| SCHEMBL2052756 | 0.80 | L3MBTL1 (0.45) | ALDH1A1TSHRSMN1; SMN2KMT2A | |
| SCHEMBL6587934 | 0.80 | KMT2A (0.47) | ALDH1A1TSHRSMN1; SMN2KMT2AMMP8 | |
| SCHEMBL28973626 | 0.79 | DPP4 (0.42) | DPP4DPP9KMT2AKCNH2 | |
| SCHEMBL26288572 | 0.79 | ALDH1A1 (0.45) | ALDH1A1TSHRSMN1; SMN2DPP4KMT2A | |
| SCHEMBL16342407 | 0.79 | TSHR (0.41) | ALDH1A1TSHRSMN1; SMN2KMT2AMMP8 | |
| SCHEMBL2842757 | 0.78 | DPP4 (0.45) | ALDH1A1TSHRSMN1; SMN2DPP4KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230279008-A1 | PTGR2 INHIBITORS AND THEIR USE | NATIONAL TAIWAN UNIVERSITY (TW) | 2023-09-07 | — | — | US | disclosed |
| US-20230279008-A1 | PTGR2 INHIBITORS AND THEIR USE | NATIONAL TAIWAN UNIVERSITY (TW) | 2023-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230279008-A1 | PTGR2 INHIBITORS AND THEIR USE | PTGFR, PTGIR, PTGDR2 | ALDH1A1 1177/4885TSHR 270/4885SMN1; SMN2 4504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.